Lonza Group (LO3A) AI Stock Analysis
Lonza Group
(Frankfurt:LO3A)
No summary available
Lonza Group (LO3A) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 58.27B
- Dividend Yield
- 0.70%
- Average Volume (3M)
- 64
- Price to Earnings (P/E)
- -436.6
- Beta (1Y)
- 0.61
- Revenue Growth
- -9.04%
- EPS Growth
- -113.60%
- Country
- Germany
- Employees
- 16,866
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lonza Group Business Overview & Revenue Model
Company Description
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment...
Lonza Group Earnings Call Summary
The call emphasized strong, broad-based organic growth, meaningful margin expansion, and a large improvement in free cash flow, supported by strategic portfolio moves (divestment) and targeted growth investments. Near-term headwinds include FX effects, site-specific shutdowns and ramp-related margin dilution, and elevated working capital. Management reiterated disciplined capital allocation and an upgraded margin outlook, while cautioning that H2 will likely see normalized growth rates and margins versus an unusually strong H1. Overall the positives (robust growth, profitability, cash flow and strategic clarity) materially outweigh the operational and timing-related drawbacks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance: Lonza upgraded its full‑year 2026 CORE EBITDA margin to 33–34% and reconfirmed 11–12% CER sales growth for the year; H1 trading underpins this with sales of CHF 3.4bn (CER +16%), CORE EBITDA of CHF 1.2bn (CORE EBITDA +27.4% vs H1 2025) and a CORE EBITDA margin of 34.8% (+4.4pp). Free cash flow rose to CHF 426m (vs CHF 116m prior year, ≈+CHF310m), ROIC improved to 13.2% (≈+3pp), and H1 CapEx was CHF 530m (15.7% of sales, ~60% into growth projects). Platform metrics: Integrated Biologics CHF 1.87bn (CER +10%, CORE EBITDA CHF 674m, margin 36%); Advanced Synthesis CHF 834m (CER +27.7%, CORE EBITDA CHF 401m, margin 48.1%); Specialized Modalities CHF 553m (CER +22.6%, CORE EBITDA CHF 155m, margin 28%). Other guidance/assumptions: FY FX headwind of ~‑2 to ‑3pp (H1 FX hit ~‑5pp, AER sales +11.2%), Vacaville ~CHF 0.6bn FY sales, trade working capital 37.9% of sales, organic CapEx >CHF 7bn to 2030 with ongoing mid–high‑teens % of sales investment, project return targets IRR ≥15% and peak ROIC ≥30%, and key project ramp timelines (Visp payload linker ~ramp 2029; Stein ADC fill ~ramp 2030; peak sales by mid‑2030s).
Lonza Group Peers Comparison
Overall Rating
REGN81Outperform
HALO76Outperform
MRNA67Neutral
BMRN56Neutral
BNTX49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| REGN | 81Outperform | $96.26B | 19.23 | 15.07% | 0.41% | 18.59% | 8.14% |
| HALO | 76Outperform | $14.79B | 29.28 | 180.63% | ― | 41.15% | -21.44% |
| MRNA | 67Neutral | $103.15B | -30.26 | -39.20% | ― | -27.62% | -6.22% |
| BMRN | 56Neutral | $11.07B | -623.55 | -0.31% | ― | 19.76% | -103.57% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BNTX | 49Neutral | $22.49B | -13.11 | -8.09% | ― | -20.72% | -160.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LO3A | Lonza | 69.50 | 12.88 | 22.74% | |
| BMRN | Biomarin Pharmaceutical Inc. | 56.12 | 3.45 | 6.55% | |
| HALO | Halozyme Therapeutics | 122.96 | 54.95 | 80.80% | |
| REGN | Regeneron Pharmaceuticals | 902.90 | 251.50 | 38.61% | |
| MRNA | Moderna | 241.46 | 216.70 | 875.20% | |
| BNTX | Biontech Se Sponsored Adr | 85.86 | -19.21 | -18.28% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.